Market Overview:
The global oncology treatment drug market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to factors such as increasing incidence of cancer, rising demand for novel and targeted therapies, and growing awareness about cancer treatments. The chemotherapy segment is expected to dominate the global oncology treatment drug market during the forecast period. This can be attributed to the high prevalence of blood cancers and their relatively easy treatment with chemotherapy drugs. The targeted therapy segment is projected to grow at a higher CAGR than other segments during the forecast period owing to its ability to specifically target tumor cells and provide better outcomes than traditional chemotherapy drugs. Geographically, North America dominates the global oncology treatment drug market followed by Europe due high incidence rate of various types of cancers in these regions.
Product Definition:
Oncology is the study of cancer and its treatment. Treatment drugs are used to kill or stop the growth of cancer cells.
Chemotherapy:
Chemotherapy is a group of medical procedures used to treat cancer. Chemotherapies mainly include drug therapy and radiation therapy. Drug therapies comprise anti-cancer drugs, alkylating agents, cytotoxic agents, plant derivatives or natural products, and others. Radiation on the other hand includes external beam radiation therapy (EBRT), intraoperative radiotherapy (IORT), radioisotope treatment (RIT), and brachytherapy among others.
Targeted Therapy:
Targeted therapy is a type of chemotherapy that delivers drugs only to cancer cells, tissues or organs that can be removed or isolated from the rest of the body. Targeted therapy includes drug delivery systems such as monoclonal antibodies, small molecule drugs and natural products.
The global oncology treatment drug market is expected to grow at a lucrative rate during the forecast period owing to factors such as increasing prevalence of cancer and growing geriatric population base across the globe.
Application Insights:
Breast cancer held the largest share of revenue in 2017 owing to the increasing prevalence of breast cancer and introduction of several new drugs. Breast cancers are commonly diagnosed in developed countries while under-diagnosed in developing countries due to lack of awareness and availability of affordable healthcare. This is expected to result in high adoption rate for targeted therapy, chemotherapy, hormonal therapy, and other therapies for breast cancer patients from 2018 to 2030.
The gastrointestinal segment is expected witness lucrative growth over the forecast period due largely to an increase in demand for R&D initiatives pertaining towards finding a cure or treatment methodologies specific against GI cancers such as Helicobacter pylori infection which causes ulcers & gastritis along with its eradication from human body through various research initiatives undertaken by global oncology companies & institutions together with government support.
Regional Analysis:
North America dominated the global oncology treatment drug market in 2017. This can be attributed to the presence of key players, increased R&D investments by them, and high adoption rate for new technologies. The U.S., which is at the forefront of North America, accounted for a revenue share of over 80% in 2017 owing to an increase in awareness about early diagnosis and implementation of novel therapies resulting in higher revenue generation from this region.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to factors such as increasing healthcare expenditure levels coupled with rising patient awareness levels regarding available oncology treatments leading towards improved revenue generation from this region during the forecast period. Moreover, economic development within countries such as India & China has led towards improvement in healthcare infrastructure along with growing research initiatives undertaken by major pharmaceutical companies thereby contributing significantly towards regional growth over the next eight years (2030).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for oncology treatment drug market. According to World Health Organization (WHO), the number of new cases diagnosed with cancer is expected to rise from 14 million in 2012 to 22 million by 2030. This will create a huge demand for oncology drugs and boost the growth of oncology treatment drug market.
- Rising awareness about early diagnosis and treatment: There is an increasing awareness among people about early diagnosis and treatment of cancer, which is propelling the demand for oncology drugs. Moreover, governments are also investing in health care infrastructure, which is aiding in the growth of this market.
- Technological advancements: The technological advancements in diagnostics and therapeutics are providing impetus to the growth of this market as they are helping in better detection and treatment of cancers respectively. For instance, developmentof targeted therapies such as monoclonal antibodies has revolutionizedcancer therapyand led to increased survival rates among patients with various typesof cancers .Thisis likelyto drivethegrowthoftheoncologytreatmentdrugmarketinthefuture .
Scope Of The Report
Report Attributes
Report Details
Report Title
Oncology Treatment Drug Market Research Report
By Type
Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, Others
By Application
Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory/Lung Cancer, Others
By Companies
Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, AbbVie, Takeda, Astellas, Ipsen, Sanofi, Bayer, Biogen Idec, Teva, Otsuka, Eisai, Merck KGaA, Gilead Sciences
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
243
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Oncology Treatment Drug Market Report Segments:
The global Oncology Treatment Drug market is segmented on the basis of:
Types
Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory/Lung Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Celgene
- Novartis
- Bristol-Myers Squibb
- Johnson & Johnson
- Merck & Co.
- AstraZeneca
- Pfizer
- Amgen
- Eli Lilly
- AbbVie
- Takeda
- Astellas
- Ipsen
- Sanofi
- Bayer
- Biogen Idec
- Teva
- Otsuka
- Eisai
- Merck KGaA
- Gilead Sciences
Highlights of The Oncology Treatment Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemotherapy
- Targeted Therapy
- Immunotherapy (Biologic Therapy)
- Hormonal Therapy
- Others
- By Application:
- Blood Cancer
- Breast Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Respiratory/Lung Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oncology Treatment Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oncology treatment drugs are medications used to treat cancer. They can be divided into two groups: targeted therapy and chemotherapy.
Some of the key players operating in the oncology treatment drug market are Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, AbbVie, Takeda, Astellas, Ipsen, Sanofi, Bayer, Biogen Idec, Teva, Otsuka, Eisai, Merck KGaA, Gilead Sciences.
The oncology treatment drug market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Oncology Treatment Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Oncology Treatment Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Oncology Treatment Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Oncology Treatment Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Oncology Treatment Drug Market Size & Forecast, 2020-2028
4.5.1 Oncology Treatment Drug Market Size and Y-o-Y Growth
4.5.2 Oncology Treatment Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Chemotherapy
5.2.2 Targeted Therapy
5.2.3 Immunotherapy (Biologic Therapy)
5.2.4 Hormonal Therapy
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Blood Cancer
6.2.2 Breast Cancer
6.2.3 Gastrointestinal Cancer
6.2.4 Prostate Cancer
6.2.5 Respiratory/Lung Cancer
6.2.6 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Oncology Treatment Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Oncology Treatment Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Chemotherapy
9.6.2 Targeted Therapy
9.6.3 Immunotherapy (Biologic Therapy)
9.6.4 Hormonal Therapy
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Blood Cancer
9.10.2 Breast Cancer
9.10.3 Gastrointestinal Cancer
9.10.4 Prostate Cancer
9.10.5 Respiratory/Lung Cancer
9.10.6 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Chemotherapy
10.6.2 Targeted Therapy
10.6.3 Immunotherapy (Biologic Therapy)
10.6.4 Hormonal Therapy
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Blood Cancer
10.10.2 Breast Cancer
10.10.3 Gastrointestinal Cancer
10.10.4 Prostate Cancer
10.10.5 Respiratory/Lung Cancer
10.10.6 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Chemotherapy
11.6.2 Targeted Therapy
11.6.3 Immunotherapy (Biologic Therapy)
11.6.4 Hormonal Therapy
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Blood Cancer
11.10.2 Breast Cancer
11.10.3 Gastrointestinal Cancer
11.10.4 Prostate Cancer
11.10.5 Respiratory/Lung Cancer
11.10.6 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Chemotherapy
12.6.2 Targeted Therapy
12.6.3 Immunotherapy (Biologic Therapy)
12.6.4 Hormonal Therapy
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Blood Cancer
12.10.2 Breast Cancer
12.10.3 Gastrointestinal Cancer
12.10.4 Prostate Cancer
12.10.5 Respiratory/Lung Cancer
12.10.6 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Chemotherapy
13.6.2 Targeted Therapy
13.6.3 Immunotherapy (Biologic Therapy)
13.6.4 Hormonal Therapy
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Blood Cancer
13.10.2 Breast Cancer
13.10.3 Gastrointestinal Cancer
13.10.4 Prostate Cancer
13.10.5 Respiratory/Lung Cancer
13.10.6 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Oncology Treatment Drug Market: Competitive Dashboard
14.2 Global Oncology Treatment Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche
14.3.2 Celgene
14.3.3 Novartis
14.3.4 Bristol-Myers Squibb
14.3.5 Johnson & Johnson
14.3.6 Merck & Co.
14.3.7 AstraZeneca
14.3.8 Pfizer
14.3.9 Amgen
14.3.10 Eli Lilly
14.3.11 AbbVie
14.3.12 Takeda
14.3.13 Astellas
14.3.14 Ipsen
14.3.15 Sanofi
14.3.16 Bayer
14.3.17 Biogen Idec
14.3.18 Teva
14.3.19 Otsuka
14.3.20 Eisai
14.3.21 Merck KGaA
14.3.22 Gilead Sciences
